Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Pharmos (PARS) -- Ignore unavailable to you. Want to Upgrade?

To: Dr. John M. de Castro who wrote (244)	11/24/1998 12:40:00 PM
From: wolfdog2	Respond to of 1386

John, I think Richard has the better argument. Fact is the analysts do know that SNX-111 failed. The failure may eventually be good news for the company, but is bad news in the short term for the stock. Remember, for SNX-111 to have made it into P3, it had successfully complete P2. And that little tidbit is what is going to influence the price of PARS's stock. It may also influence the size of any upfront payment that PARS will receive in a partnering agreement. Hell, what company will want to dump a lot of money into a minefield where competitors have been blowing up left and right? So, I would expect moderate upfront payments, with larger milestone payments.